- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.04. | Australia's Kazia pays research institute $1.4M for epigenetic platform, preclinical drug | ||
| 13.04. | FDA urges clinical trial sponsors to report the results of their studies | ||
| 13.04. | Kailera outlines plans for $528.5M IPO to support quartet of Chinese obesity assets | ||
| 13.04. | Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda's Entyvio | ||
| 13.04. | AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets | ||
| 13.04. | Revolution's much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial | ||
| 13.04. | Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial | ||
| 13.04. | Regeneron rides into radiopharma via $2.1B biobucks pact with Australia's Telix | ||
| 13.04. | BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types | ||
| 10.04. | FDA rejects Replimune's melanoma prospect for second time | ||
| 10.04. | China's Oricell raises $100M for carcinoma CAR-T plans ahead of IPO push | ||
| 09.04. | Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline | ||
| 09.04. | Avalyn plans IPO to fund phase 3 trials of inhaled versions of approved respiratory drugs | ||
| 08.04. | Jeito hails $1.2B as 'largest raise ever' for independent biopharma-focused European fund | ||
| 07.04. | Lilly pays AC Immune $12.5M to expand Alzheimer's collab as asset draws closer to clinic | ||
| 07.04. | Gilead pays $3.1B upfront for Tubulis to bolster oncology ADC pipeline | ||
| 07.04. | Sanofi's bispecific scores double respiratory phase 2 wins, but flunks eczema study | ||
| 06.04. | Takeda tears up Denali partnership, returning dementia asset amid restructuring | ||
| 06.04. | Anthropic acquires stealth AI startup Coefficient Bio in $400M deal: reports | ||
| 03.04. | Months after $100M series A, Syneron closes $150M round to support peptide platform | ||
| 03.04. | Biopharma R&D pipeline shrinks for 1st time in 30 years: report | ||
| 02.04. | 'Portfolio assessment' prompts Ferring to terminate 2 fertility trials | ||
| 02.04. | Immunovant's FcRn inhibitor flunks phase 3 eye disease trials, validating biotech's waning interest | ||
| 02.04. | Alto halts work on PDE4 inhibitor after phase 2 schizophrenia failure | ||
| 01.04. | Gilead cancels midstage HIV trial as FDA's clinical hold remains intact |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.